Brand name: Zavesca TM
Active ingredients: miglustat
What it is used for
Zavesca is indicated for the oral treatment of patients with mild to moderate Type 1 Gaucher disease, for whom enzyme replacement therapy is not a therapeutic option. ZAVESCA is indicated for the treatment of the progressive neurological manifestations in adult and paediatric patients with Niemann-Pick type C disease.
How to take it
The way to take this medicine is: Oral. This medicine is taken by mouth.
- Store below 30 degrees Celsius
- Shelf lifetime is 5 Years.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White capsule with "OGT918" printed in black on the cap and "100" printed on the body.
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Pregnant or planning a pregnancy?
For the active ingredient miglustat
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Consumer Medicines Information (CMI)
For side effects, taking other medicines and more
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems